These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37402468)

  • 41. An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries.
    Ward LM; Chambers A; Mechichi E; Wong-Rieger D; Campbell C
    Orphanet J Rare Dis; 2022 Mar; 17(1):113. PubMed ID: 35246200
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antisense oligonucleotides: a novel Frontier in pharmacological strategy.
    Collotta D; Bertocchi I; Chiapello E; Collino M
    Front Pharmacol; 2023; 14():1304342. PubMed ID: 38044945
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug development for orphan diseases in the context of personalized medicine.
    Brewer GJ
    Transl Res; 2009 Dec; 154(6):314-22. PubMed ID: 19931198
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Developing therapies for rare tumors: opportunities, challenges and progress.
    Bradford D; Reilly KM; Widemann BC; Sandler A; Kummar S
    Expert Opin Orphan Drugs; 2016; 4(1):93-103. PubMed ID: 32765971
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
    Michaeli DT; Michaeli T; Albers S; Boch T; Michaeli JC
    Eur J Health Econ; 2024 Aug; 25(6):979-997. PubMed ID: 37962724
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of the rare disease and Orphan Drug Act in Taiwan.
    Hsiang NC; Huang WF; Gau CS; Tsai TW; Chang LC
    J Food Drug Anal; 2021 Dec; 29(4):717-725. PubMed ID: 35649145
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Access to medicines for rare diseases: regulatory aspects and public health priorities.].
    Costa E; Grimaldi G; Del Grosso V; Isgrò A; Genazzani A
    Recenti Prog Med; 2022; 113(7):415-424. PubMed ID: 35852076
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
    Tambuyzer E
    Nat Rev Drug Discov; 2010 Dec; 9(12):921-9. PubMed ID: 21060315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Orphan drugs: major development challenges at the clinical stage.
    Fonseca DA; Amaral I; Pinto AC; Cotrim MD
    Drug Discov Today; 2019 Mar; 24(3):867-872. PubMed ID: 30658132
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preparing for the Future of Rare Diseases.
    Groft SC; Posada de la Paz M
    Adv Exp Med Biol; 2017; 1031():641-648. PubMed ID: 29214596
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Affordable orphan drugs: a role for not-for-profit organizations.
    Davies EH; Fulton E; Brook D; Hughes DA
    Br J Clin Pharmacol; 2017 Jul; 83(7):1595-1601. PubMed ID: 28109021
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recommendations for the design of small population clinical trials.
    Day S; Jonker AH; Lau LPL; Hilgers RD; Irony I; Larsson K; Roes KC; Stallard N
    Orphanet J Rare Dis; 2018 Nov; 13(1):195. PubMed ID: 30400970
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review.
    Grand TS; Ren S; Hall J; Åström DO; Regnier S; Thokala P
    Pharmacoeconomics; 2024 Jun; 42(6):619-631. PubMed ID: 38616217
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Orphan drugs: the regulatory environment.
    Franco P
    Drug Discov Today; 2013 Feb; 18(3-4):163-72. PubMed ID: 22981668
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Orphan drug policy analysis in China.
    Liu M; Lu Y; Li J; Zhang Y; Zhang S; Liu Y
    Front Pharmacol; 2024; 15():1278710. PubMed ID: 38939834
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Review of 11 national policies for rare diseases in the context of key patient needs.
    Dharssi S; Wong-Rieger D; Harold M; Terry S
    Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.